1	Indique	indicar	VMSP3S0	-	-	174-181	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
2	que	que	CS	-	-	182-185	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
3	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#régimen/tratamiento	186-197	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
4	está	estar	VAIP3S0	-	-	198-202	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
5	contraindicado	contraindicar	VMP00SM	-	-	203-217	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
6	:	:	Fd	-	-	217-218	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
7	A	a	SPS00	-	-	0-1	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
8	una	una		C0205447_1	calificador_1	2-5	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
9	mujer	mujer	NCFS000	C0043210#C0015780#C0086418	persona#hallazgo#estructura_corporal#organismo_vivo	6-11	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
10	de	de	SPS00	C0332285	atributo	12-14	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
11	35	35		-	-	15-17	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
12	años	año	NCMP000	C0439234	calificador	18-22	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
13	se	se	P00CN000	-	-	23-25	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
14	realiza	realizar	VMIP3S0	-	-	26-33	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
15	una	una		C0205447_1	calificador_1	34-37	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
16	citología	citología	NCFS000	-	-	38-47	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
17	vaginal	vaginal	AQ0CS0	-	-	48-55	417_QUEST_clinical_caseMIR	SENT1	B-Estructura_Corporal	-	-	-	-
18	tras	tras	SPS00	-	-	56-60	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
19	5	5		-	-	61-62	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
20	años	año	NCMP000	C0439234	calificador	63-67	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
21	sin	sin	SPS00	C0332288	atributo	68-71	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
22	control	control	NCMS000	C2587213	atributo	72-79	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
23	previo	previo	AQ0MS0	C0205156	calificador	80-86	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
24	y	y	CC	C1706368	calificador	87-88	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
25	el	el	DA0MS0	-	-	89-91	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
26	diagnóstico	diagnóstico	NCMS000	C0011900	entidad_observable	92-103	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
27	es	ser	VSIP3S0	-	-	104-106	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
28	SIL	sil	NCMS000	-	-	107-110	417_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-	-	-	-
29	(	(	Fpa	-	-	111-112	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
30	lesión	lesión	NCFS000	C0332447#C1313971#C0221198	anomalía_morfológica	112-118	417_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-	-	-	-
31	intraepitelial	intraepitelial	AQ0CS0	-	-	119-133	417_QUEST_clinical_caseMIR	SENT1	B-Calificador	-	30	4645	LOC
32	)	)	Fpt	-	-	133-134	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
33	de	de	SPS00	C0332285	atributo	135-137	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
34	alto	alto	NCMS000	C0205082_1	calificador_1	138-142	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
35	grado	grado	NCMS000	C0205082_2	calificador_2	143-148	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-
36	.	.	Fp	-	-	148-149	417_QUEST_clinical_caseMIR	SENT1	-	-	-	-	-

